61N1 Stock Overview
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
StageZero Life Sciences Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.015 |
52 Week High | CA$0.065 |
52 Week Low | CA$0.015 |
Beta | 0.29 |
1 Month Change | -31.11% |
3 Month Change | -13.89% |
1 Year Change | -75.20% |
3 Year Change | -98.23% |
5 Year Change | -97.67% |
Change since IPO | -98.32% |
Recent News & Updates
Recent updates
Shareholder Returns
61N1 | DE Biotechs | DE Market | |
---|---|---|---|
7D | -26.2% | 0.06% | 0.07% |
1Y | -75.2% | 28.6% | 4.9% |
Return vs Industry: 61N1 underperformed the German Biotechs industry which returned 28.6% over the past year.
Return vs Market: 61N1 underperformed the German Market which returned 4.9% over the past year.
Price Volatility
61N1 volatility | |
---|---|
61N1 Average Weekly Movement | 32.4% |
Biotechs Industry Average Movement | 5.8% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 61N1's share price has been volatile over the past 3 months.
Volatility Over Time: 61N1's weekly volatility (32%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 40 | James Howard-Tripp | https://www.stagezerolifesciences.com |
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company’s lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood.
StageZero Life Sciences Ltd. Fundamentals Summary
61N1 fundamental statistics | |
---|---|
Market cap | €3.36m |
Earnings (TTM) | -€11.54m |
Revenue (TTM) | €2.65m |
1.4x
P/S Ratio-0.3x
P/E RatioIs 61N1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
61N1 income statement (TTM) | |
---|---|
Revenue | US$2.88m |
Cost of Revenue | US$2.85m |
Gross Profit | US$29.99k |
Other Expenses | US$12.56m |
Earnings | -US$12.53m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.10 |
Gross Margin | 1.04% |
Net Profit Margin | -434.85% |
Debt/Equity Ratio | -15.0% |
How did 61N1 perform over the long term?
See historical performance and comparison